Clover Health Investments, CORP /DE Form 4 insider transactions

Clover Health CEO Andrew Toy disposed of 308,950 Class A Common Stock shares on October 1, 2025, to cover tax obligations related to RSU vesting.

Jamie L. Reynoso, Clover Health's CEO of Medicare Advantage, sold 4,914 shares of Class A Common Stock for $3.09 per share under a Rule 10b5-1 trading plan.

Clover Health's General Counsel, Karen Soares, had 6,403 shares withheld to cover tax obligations upon the vesting of restricted stock units.

Clover Health's CEO, Medicare Advantage, Jamie L. Reynoso, reported the disposition of Class A Common Stock for tax obligations related to RSU vesting.

Clover Health's CEO, Jamie L. Reynoso, filed an amended Form 4 to correct the reported number of shares withheld for tax obligations related to RSU vesting.

Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, reported an amended acquisition of 518,000 Class A Common Stock through restricted stock units, reflecting higher performance achievement.

Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, disposed of 52,967 Class A Common Stock shares to cover tax liabilities from RSU vesting.

Clover Health CEO Conrad Wai filed a Form 4 detailing a future disposition of 98,412 shares for tax obligations from RSU vesting on September 14, 2025.

Clover Health's General Counsel, Karen Soares, disposed of 7,459 Class A Common Stock shares at $2.57 each to cover tax obligations related to RSU vesting.

Clover Health Director Anna U. Loengard acquired 26,500 shares of Class A Common Stock through family IRAs, while also reporting a reduction in beneficial interest due to an ex-spouse's holdings.

Clover Health CEO Andrew Toy disposed of 85,535 Class A Common Stock shares to cover tax obligations related to RSU vesting.

Clover Health Investments Director and 10% owner Vivek Garipalli acquired 446,980 shares of Class A Common Stock for approximately $1 million.

Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, sold 6,823 shares of Class A Common Stock for $2.89 per share under a pre-arranged trading plan.

Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, disposed of 29,513 shares of Class A Common Stock to cover tax obligations related to RSU vesting.

Clover Health's General Counsel, Karen Soares, amended her beneficial ownership filing to reflect the full achievement and vesting of performance-based restricted stock units.

Clover Health Investments Corp. CEO Conrad Wai reported a disposition of 27,930 Class A Common Stock shares to cover tax obligations related to RSU vesting.

Clover Health's CEO of Home Care, Brady Priest, disposed of 25,081 shares of Class A Common Stock to cover tax obligations related to RSU vesting.

Clover Health's Chief Financial Officer, Peter J. Kuipers, reported a disposition of 217,382 shares of Class A Common Stock due to tax withholding upon the vesting of restricted stock units.

Conrad Wai, CEO of Counterpart Health, a subsidiary of Clover Health Investments, Corp., has scheduled the sale of over 200,000 Class A Common Stock shares in July 2025 under a pre-arranged trading plan.

Clover Health's CEO of Home Care, Brady Priest, amended a Form 4 filing to clarify the full achievement and vesting of performance-based restricted stock units.

Clover Health Investments, Corp. CEO Conrad Wai filed an amended Form 4 detailing the vesting of performance-based restricted stock units and a future sale of shares under a pre-arranged trading plan.

Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp., sold a total of 21,801 Class A Common Stock shares and had 8,706 shares withheld for tax obligations in early July 2025, all under a Rule 10b5-1 trading plan.

Clover Health Investments, Corp. CEO Andrew Toy reported the automatic withholding of 308,950 Class A Common Stock shares to cover tax obligations related to the vesting of restricted stock units.

Clover Health Investments Corp. CEO of Medicare Advantage, Jamie L. Reynoso, reported the future vesting of 217,523 restricted stock units and the simultaneous disposition of 85,596 shares for tax purposes, effective June 30, 2025.

Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp., sold 20,450 shares of Class A Common Stock for a weighted average price of $2.86 per share, pursuant to a Rule 10b5-1 trading plan.

Clover Health Investments, Corp.'s General Counsel and Secretary, Karen Soares, reported the disposition of 6,404 Class A Common Stock shares on June 15, 2025, to cover tax obligations related to RSU vesting.

Clover Health Investments Corp. CEO Conrad Wai disposed of 98,411 Class A Common Stock shares on June 14, 2025, to cover tax obligations related to the vesting of restricted stock units.

Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp., reported the disposition of Class A Common Stock shares to cover tax obligations related to the vesting of restricted stock units.

Clover Health's CFO, Peter Kuipers, reports the acquisition of restricted stock units (RSUs) that will vest over time, according to a Form 4 filing.

Karen Soares, General Counsel & Secretary of Clover Health Investments, reports the disposal of 5,345 shares of Class A Common Stock to cover tax obligations upon RSU vesting.